Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis
{{output}}
Semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been associated with cardiovascular benefits, whereas the consistency of its effect across various clinical settings, as well as its safety-economic profile, remains uncertain.... ...
